Oh wow. Yet another RCE "holder" who posts only on RCE on HC, and always to the negative. Snort, snort.
Not quite subtle enough....
Now a decent criticism of this report would be again, the lack of clarity on the specific data from the phase II, but otherwise an extensive report on results today and the strategy and direction of the company its application.
And the company nice and clear for you on what the phase II study was on
@zecs
And indeed the specific aims of the coming phase III in Indonesia on specifically DFI foot infections that hopefully satisfies your fears as a shareholder.
(20min delay)